QUICK SEARCH:   [advanced] Author: Keyword(s):
Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents

First published online October 8, 2008
doi: 10.1242/10.1242/jcs.029223

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Richardson, C. Articles by Alessi, D. R. PubMed PubMed Citation Articles by Richardson, C. Articles by Alessi, D. R.

The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway

MRC Protein Phosphorylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK

Dario R. Alessi

MRC Protein Phosphorylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK

e-mail: c.j.z.richardson{at}dundee.ac.uk

e-mail: d.r.alessi{at}dundee.ac.uk

Accepted 19 August 2008

It has recently been shown that the WNK [with-no-K(Lys)] kinases (WNK1, WNK2, WNK3 and WNK4) have vital roles in the control of salt homeostasis and blood pressure. This Commentary focuses on recent findings that have uncovered the backbone of a novel signal-transduction network that is controlled by WNK kinases. Under hyperosmotic or hypotonic low-Cl^– conditions, WNK isoforms are activated, and subsequently phosphorylate and activate the related protein kinases SPAK and OSR1. SPAK and OSR1 phosphorylate and activate ion co-transporters that include NCC, NKCC1 and NKCC2, which are targets for the commonly used blood-pressure-lowering thiazide-diuretic and loop-diuretic drugs. The finding that mutations in WNK1, WNK4, NCC and NKCC2 cause inherited blood-pressure syndromes in humans highlights the importance of these enzymes. We argue that these new findings indicate that SPAK and OSR1 are promising drug targets for the treatment of hypertension, because inhibiting these enzymes would reduce NCC and NKCC2 activity and thereby suppress renal salt re-absorption. We also discuss unresolved and controversial questions in this field of research.

Key words: Ion co-transporters, SPAK, OSR1, WNK, Protein kinases

This article has been cited by other articles:

				Y. Wang, J. R. O'Connell, P. F. McArdle, J. B. Wade, S. E. Dorff, S. J. Shah, X. Shi, L. Pan, E. Rampersaud, H. Shen, et al. From the Cover: Whole-genome association study identifies STK39 as a hypertension susceptibility gene PNAS, January 6, 2009; 106(1): 226 - 231. [Abstract] [Full Text] [PDF]

				M. S. Balda and K. Matter Tight junctions at a glance J. Cell Sci., November 15, 2008; 121(22): 3677 - 3682. [Full Text] [PDF]